The design and synthesis of selective prostaglandin analogs as bone anabolic agents for the potential treatment of osteoporosis

David Lindsey Soper; Yili Wang; Biswanath De; Mitchell Anthony deLong; Michelle Jeanine Dirr; Michele Elaine Soehner; Mark Walden Lundy; Glen Edward Mieling; John August Wos

doi:10.1007/978-1-4615-0193-0_46

The design and synthesis of selective prostaglandin analogs as bone anabolic agents for the potential treatment of osteoporosis

Adv Exp Med Biol. 2002:507:303-7. doi: 10.1007/978-1-4615-0193-0_46.

Authors

David Lindsey Soper¹, Yili Wang, Biswanath De, Mitchell Anthony deLong, Michelle Jeanine Dirr, Michele Elaine Soehner, Mark Walden Lundy, Glen Edward Mieling, John August Wos

Affiliation

¹ Procter and Gamble Pharmaceuticals, 8700 Mason-Montgomery Road, Mason, Ohio 45040-9317, USA.

PMID: 12664601
DOI: 10.1007/978-1-4615-0193-0_46

Abstract

A series of prostaglandins selective for the human FP receptor have been synthesized and evaluated as potential therapeutics for the treatment of osteoporosis. The compounds proved to be potent (nanomolar binding affinity) and selective (> 100x) ligands for the human FP receptor in vitro, and increased bone volume in the ovariectomized rat in vivo.

MeSH terms

Bone and Bones / drug effects
Bone and Bones / physiology*
Bone and Bones / physiopathology
Drug Design
Humans
Models, Molecular
Molecular Structure
Osteoporosis / drug therapy*
Prostaglandins F, Synthetic / therapeutic use
Prostaglandins, Synthetic / chemical synthesis*
Prostaglandins, Synthetic / therapeutic use*
Structure-Activity Relationship

Substances

Prostaglandins F, Synthetic
Prostaglandins, Synthetic
fluprostenol